Clinical trials
Sickle Cell Disease clinical trials
Below are recruiting sickle cell disease clinical trials, each written for real people, not researchers. We’re tracking 172 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06529042Enrolling by invitation
Sickle Cell Risk in Pregnancy Tool Study
This study is developing a risk assessment tool to help predict complications in pregnant women with sickle cell disease. It reviews medical records from women who have received prenatal care and given birth at participating hospitals.
Baltimore, MarylandAges 16–60 - NCT06506461RecruitingPhase 1
Gene editing for sickle cell disease in young adults
This trial uses gene editing to fix your own blood stem cells, so you can stop having severe sickle cell crises. It is for young adults with frequent pain episodes or who need regular blood transfusions.
Memphis, TennesseeAges 18–24 - NCT06481306RecruitingPhase 1/Phase 2
Testing a new drug for sickle cell disease in healthy people and patients
This early-phase study tests a new drug (BMS-986470) for people with sickle cell disease who have frequent pain crises. The goal is to see if it can safely reduce crises. It includes a small group of healthy volunteers as well.
Birmingham, AlabamaAges 18 years+ - NCT06477289Recruiting
Blood vessel function and thinking in sickle cell disease
This study looks at how blood vessel function in the fingers (using a simple test called arterial tonometry) relates to thinking and memory in people with sickle cell disease. It involves a non-invasive measurement and cognitive tasks.
Memphis, TennesseeAges 12–25 - NCT06439082RecruitingPhase 3
Crizanlizumab for sickle cell pain crises
This trial tests whether crizanlizumab can reduce painful sickle cell crises (called vaso-occlusive crises or VOCs) in people with sickle cell disease who have frequent crises. It may be an option for those who still have crises despite current treatments.
Birmingham, AlabamaAges 12–100 - NCT06363760Enrolling by invitation
Long-term follow-up after EDIT-301 gene therapy
This long-term follow-up study monitors people with sickle cell disease or transfusion-dependent beta-thalassemia who have already received the gene-editing therapy EDIT-301. It helps researchers understand how safe and effective the treatment is over time.
Oakland, CaliforniaAges 12–50 - NCT06374238Recruiting
Peer support for young people with sickle cell pain
This study tests whether having a peer mentor who also has sickle cell disease can help young people manage chronic pain. You would use a mobile app to connect with your mentor and track your pain.
Mobile, AlabamaAges 16–39 - NCT06367192Recruiting
School Readiness Program for Preschoolers with Sickle Cell
This study tests a program to help preschoolers with sickle cell disease get ready for school. It looks at whether a special learning program can help with skills like paying attention and getting along with others.
Memphis, TennesseeAges 3.5 years–6.5 years - NCT06358638RecruitingPhase 2
Sickle cell transplant using a gentler approach for patients with donor antibodies
This trial is testing a new, gentler type of bone marrow transplant for children and young adults with sickle cell disease who have a healthy sibling donor with a mismatched blood type or who have antibodies against their donor's red blood cells. The goal is to replace the faulty bone marrow with healthy donor cells, with fewer side effects than traditional transplants.
Washington D.C., District of ColumbiaAges 2–25 - NCT06318143Recruiting
Increasing use of hydroxyurea for sickle cell in Nigeria
This study aims to help more people with sickle cell disease in Nigeria start taking hydroxyurea, a medicine that can prevent pain crises and other complications. It will work with clinics to make it easier for patients to get and stay on this treatment.
AbujaAges 1 year+ - NCT06313398RecruitingEarly Phase 1
Measuring red blood cell lifespan in sickle cell disease
This study uses a harmless vitamin (biotin) to label your red blood cells and track how long they survive. It aims to understand how different blood disorders affect red blood cell lifespan, which may help improve treatments.
Bethesda, MarylandAges 18–100 - NCT06260891RecruitingPhase 2
Zinc study for sickle cell disease and bone health
This study tests if taking zinc supplements can improve bone health in people with sickle cell disease. It's for those with certain types of sickle cell disease (SS or S-Beta zero thalassemia) who are not on chronic transfusions or zinc supplements.
Oakland, CaliforniaAges 15–40 - NCT05519111RecruitingPhase 2
Cannabinoid treatment to lower inflammation and sickle pain
This Phase 2 study tests a cannabinoid medicine (dronabinol) to reduce inflammation and pain related to sickle cell disease. It may help you have less pain that interferes with daily life if you meet the study requirements and can safely avoid cannabis during the study.
New York, New YorkAges 18 years+ - NCT06198712RecruitingPhase 2
Testing etavopivat in children with sickle cell disease
This trial tests a new drug, etavopivat, to see how it works in children with sickle cell disease. It may help reduce painful crises and other complications.
Toronto, OntarioAges 6 months–18 years - NCT06184126Recruiting
Virtual reality for sickle cell pain in the emergency room
This trial tests whether using a virtual reality (VR) headset, along with your usual pain treatment, can help reduce pain during a sickle cell crisis. It is for adults with sickle cell disease who are in the emergency department and receiving IV opioids for a vaso-occlusive crisis.
Baltimore, MarylandAges 18 years+ - NCT06139510Recruiting
Understanding Pain in Sickle Cell Disease
This study looks at what causes pain in people with sickle cell disease. They hope to learn more about pain patterns to better help patients manage it.
Durham, North CarolinaAges 15–40 - NCT06071377Recruiting
Learning About Health in People With Sickle Cell Trait
This study is for adults who have or might have sickle cell trait (carrying the sickle cell gene but not the disease). It aims to understand the health effects of sickle cell trait over time by following participants and collecting health information.
Birmingham, AlabamaAges 18 years+ - NCT06016634RecruitingPhase 2
Alendronate for bone damage in adults with sickle cell disease
This trial tests if the drug alendronate can help heal bone damage caused by sickle cell disease. It may be an option if you have this bone problem and are between 18 and 80 years old.
Sacramento, CaliforniaAges 18–80 - NCT05953584RecruitingPhase 2
Etavopivat for preventing stroke risk in sickle cell children
This trial studies etavopivat to see if it can improve blood-flow measurements in the brain that predict future stroke risk in children with sickle cell disease. If you qualify, you would take the study medicine and be monitored with brain blood-flow testing.
Raipur, ChhattisgarhAges 12–16 - NCT05904093RecruitingPhase 1
Testing a new pill for sickle cell disease safety
This study tests a medication called fostamatinib to see if it is safe and tolerable for people with sickle cell disease. It may offer a new treatment option for managing the condition.
Bethesda, MarylandAges 18–65 - NCT05810181Recruiting
Interviews to improve choices about gene therapy for rare diseases
This study uses one-on-one interviews to learn what families and clinicians need to make decisions about gene therapy for rare diseases. The goal is to create or improve decision tools that make gene therapy information easier to understand and act on.
Memphis, TennesseeAges 8 years+ - NCT05736419RecruitingPhase 2
Immune-suppressing treatment before stem cell transplant for blood disorders
This Phase 2 study tests an immune-suppressing treatment for people with sickle cell disease or beta-thalassemia who are preparing for a stem cell transplant from a donor. It aims to help the transplant work better by changing the immune response.
Basking Ridge, New JerseyAges 2–50 - NCT05583721RecruitingPhase 2
PET scan study of heart filling and blood flow in sickle cell
This study uses a PET scan to look for links between abnormal heart “filling” problems and how well blood reaches the heart muscle in people with sickle cell disease. The results may help explain early heart changes in sickle cell and guide future care.
Memphis, TennesseeAges 18–21 - NCT04166526Recruiting
Brain and brain-vessel MRI study in kids with sickle cell
This study uses MRI scans to understand how the brain and blood vessels are affected in children with sickle cell disease, including before and after certain treatments. It also includes healthy children for comparison and may help improve future monitoring and care.
Boston, MassachusettsAges 8–18
Hear when a new Sickle Cell Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for sickle cell disease?
- Yes. Clin2 currently lists 172 recruiting sickle cell disease studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a sickle cell disease trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a sickle cell disease trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.